NIKA Quote, Financials, Valuation and Earnings

Imunon has a net margin of -35128.21% compared to Nika Pharmaceuticals's net margin of --. Nika Pharmaceuticals's return on equity of -- beat Imunon's return on equity of --.

Nika Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand Imunon has an analysts' consensus of $10.25 which suggests that it could grow by 1598.99%. Given that Imunon has higher upside potential than Nika Pharmaceuticals, analysts believe Imunon is more attractive than Nika Pharmaceuticals.

Nika Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Imunon has a beta of 1.927, suggesting its more volatile than the S&P 500 by 92.726%.

Nika Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Imunon offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nika Pharmaceuticals pays -- of its earnings as a dividend. Imunon pays out -- of its earnings as a dividend.

Nika Pharmaceuticals quarterly revenues are $160, which are larger than Imunon quarterly revenues of --. Nika Pharmaceuticals's net income of -$13K is higher than Imunon's net income of -$4.1M. Notably, Nika Pharmaceuticals's price-to-earnings ratio is 34,500.00x while Imunon's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nika Pharmaceuticals is -- versus 15.97x for Imunon. Usually stocks with elevated PS ratios are considered overvalued.

MetaVia has a net margin of -35128.21% compared to Nika Pharmaceuticals's net margin of --. Nika Pharmaceuticals's return on equity of -- beat MetaVia's return on equity of --.

Nika Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand MetaVia has an analysts' consensus of $14.33 which suggests that it could grow by 2027.55%. Given that MetaVia has higher upside potential than Nika Pharmaceuticals, analysts believe MetaVia is more attractive than Nika Pharmaceuticals.

Nika Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison MetaVia has a beta of 0.214, suggesting its less volatile than the S&P 500 by 78.621%.

Nika Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MetaVia offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nika Pharmaceuticals pays -- of its earnings as a dividend. MetaVia pays out -- of its earnings as a dividend.

Nika Pharmaceuticals quarterly revenues are $160, which are larger than MetaVia quarterly revenues of --. Nika Pharmaceuticals's net income of -$13K is higher than MetaVia's net income of -$3.7M. Notably, Nika Pharmaceuticals's price-to-earnings ratio is 34,500.00x while MetaVia's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nika Pharmaceuticals is -- versus -- for MetaVia. Usually stocks with elevated PS ratios are considered overvalued.

Tivic Health Systems has a net margin of -35128.21% compared to Nika Pharmaceuticals's net margin of -2145.71%. Nika Pharmaceuticals's return on equity of -- beat Tivic Health Systems's return on equity of -192.41%.

Nika Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand Tivic Health Systems has an analysts' consensus of -- which suggests that it could fall by --. Given that Nika Pharmaceuticals has higher upside potential than Tivic Health Systems, analysts believe Nika Pharmaceuticals is more attractive than Tivic Health Systems.

Nika Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tivic Health Systems has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Nika Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tivic Health Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nika Pharmaceuticals pays -- of its earnings as a dividend. Tivic Health Systems pays out -- of its earnings as a dividend.

Nika Pharmaceuticals quarterly revenues are $160, which are smaller than Tivic Health Systems quarterly revenues of $70K. Nika Pharmaceuticals's net income of -$13K is higher than Tivic Health Systems's net income of -$1.5M. Notably, Nika Pharmaceuticals's price-to-earnings ratio is 34,500.00x while Tivic Health Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nika Pharmaceuticals is -- versus 3.35x for Tivic Health Systems. Usually stocks with elevated PS ratios are considered overvalued.

Vycor Medical has a net margin of -35128.21% compared to Nika Pharmaceuticals's net margin of -8.84%. Nika Pharmaceuticals's return on equity of -- beat Vycor Medical's return on equity of --.

Nika Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand Vycor Medical has an analysts' consensus of -- which suggests that it could fall by --. Given that Nika Pharmaceuticals has higher upside potential than Vycor Medical, analysts believe Nika Pharmaceuticals is more attractive than Vycor Medical.

Nika Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vycor Medical has a beta of -0.416, suggesting its less volatile than the S&P 500 by 141.563%.

Nika Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vycor Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nika Pharmaceuticals pays -- of its earnings as a dividend. Vycor Medical pays out -- of its earnings as a dividend.

Nika Pharmaceuticals quarterly revenues are $160, which are smaller than Vycor Medical quarterly revenues of $436.4K. Nika Pharmaceuticals's net income of -$13K is higher than Vycor Medical's net income of -$38.6K. Notably, Nika Pharmaceuticals's price-to-earnings ratio is 34,500.00x while Vycor Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nika Pharmaceuticals is -- versus 2.53x for Vycor Medical. Usually stocks with elevated PS ratios are considered overvalued.